GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Inventories, Raw Materials & Components

Aurinia Pharmaceuticals (FRA:IKAP) Inventories, Raw Materials & Components : €0.7 Mil (As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Inventories, Raw Materials & Components?

Aurinia Pharmaceuticals's inventories, raw materials & components for the quarter that ended in Mar. 2025 was €0.7 Mil.

Aurinia Pharmaceuticals's quarterly raw materials increased from Sep. 2024 (€1.5 Mil) to Dec. 2024 (€1.6 Mil) but then declined from Dec. 2024 (€1.6 Mil) to Mar. 2025 (€0.7 Mil).

Aurinia Pharmaceuticals's annual raw materials declined from Dec. 2022 (€2.1 Mil) to Dec. 2023 (€1.6 Mil) but then increased from Dec. 2023 (€1.6 Mil) to Dec. 2024 (€1.6 Mil).


Aurinia Pharmaceuticals Inventories, Raw Materials & Components Historical Data

The historical data trend for Aurinia Pharmaceuticals's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Inventories, Raw Materials & Components Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.96 2.09 1.60 1.63

Aurinia Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.58 1.53 1.63 0.71

Aurinia Pharmaceuticals Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Aurinia Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
Address
14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals Headlines

No Headlines